Pain is universal. It disrupts work, time with family, and quality of life. Through innovations, we can make a difference.
Virpax® Pharmaceuticals is collaborating with the best minds of the pharmaceutical industry. Working alongside these leaders, we can improve pain management and target pain at its source.
Partner with us as we develop the next generation of pharmaceutical products that can minimize pain and improve people's lives.
Abstracts featuring DSF100 and NES100 will be presented at this year's exhibition.
Virpax has exclusive global rights to use Nanomerics’ nanotechnology for the delivery of a metabolically labile intranasal peptide for the management of Post-Traumatic Stress Disorder (PTSD).
Michèle C. Linde has been promoted to EVP, Global Corporate Governance, Chief Legal Officer & Corporate Secretary.